Lannett is one step closer to launching biosimilar insulin glargine. Recently, the company completed subject dosing in the pivotal clinical trial of biosimilar insulin glargine, a product being ...
SAN FRANCISCO -- For the first time today, Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the alliance's investigational new insulin ...
Among 475 patients randomized in a 1:1:1:1 fashion, those on one of three doses of injectable tirzepatide -- 5 mg, 10 mg, or 15 mg -- in addition to insulin glargine saw a significantly greater mean ...
"Continuing to research our medicines beyond the initial clinical trial program is important for patients and for the ongoing study of diabetes," said Brad Woodward, M.D., senior medical director, ...
The U.S. Food and Drug Administration has approved the first biosimilar form of insulin for adults with diabetes type 2, and adults and pediatric patients with diabetes type 1. Semglee (insulin ...
TREVOSE, Pa., Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback